L'apolipoprotéine AVÂ : un nouvel acteur du métabolisme des triglycérides

APOA5 is a new gene involved in triglycerides (TG) metabolism, discovered in 2001. Apolipoprotein AV (apoAV) is produced in the liver and circulates in plasma associated with chylomicrons, VLDL and HDL. Despite its low plasma concentrations, apoAV is a major determinant of TG variations in human populations. APOA5 polymorphisms are associated with both moderate and severe hypertriglyceridemia. APOA5 mutations were identified in hyperchylomicronemic patients and contributed to establish the role of apoAV in TG rich lipoprotein lipolysis. However, the precise function of apoAV is not yet clear: apoAV stimulates lipoprotein lipase activity, directly or indirectly, by facilitating the formation of endothelial lipolytic complexes.